Quick Answer
Aptevo Therapeutics Inc. reported Research And Development Expense of $14.54 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed an increase of +1.1% in Research And Development Expense from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Research And Development Expense has declined by 58.1%.
- Historical annual values: Fiscal year 2025: $14.54 million | Fiscal year 2024: $14.38 million | Fiscal year 2023: $17.11 million | Fiscal year 2022: $17.88 million | Fiscal year 2021: $18.99 million | Fiscal year 2020: $17.85 million | Fiscal year 2019: $24.76 million | Fiscal year 2018: $35.39 million | Fiscal year 2017: $29.02 million | Fiscal year 2016: $29.12 million | Fiscal year 2015: $34.73 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: